Coronavirus disease 2019 in Latin American patients with multiple sclerosis

Yara D. Fragoso; Irene Schiavetti; Luca Carmisciano; Marta Ponzano; Judith Steinberg; Irene Treviño-Frenk; Ethel Ciampi; Maria Cecilia A. Vecino; Edgar P. Correa; Claudia Carcamo; Sidney Gomes; Maria Lucia V. Pimentel; Gutemberg A.C. Santos; Carlos Vrech; Thereza C.A. Winckler; Maria Pia Sormani

doi:10.1016/j.msard.2021.103173

Coronavirus disease 2019 in Latin American patients with multiple sclerosis

Yara D. Fragoso, Irene Schiavetti, Luca Carmisciano, Marta Ponzano, Judith Steinberg, Irene Treviño-Frenk, Ethel Ciampi, Maria Cecilia A. Vecino, Edgar P. Correa, Claudia Carcamo, Sidney Gomes, Maria Lucia V. Pimentel, Gutemberg A.C. Santos, Carlos Vrech, Thereza C.A. Winckler, Maria Pia Sormani

A.O.U. San Martino - IST, Istituto Nazionale Ricerca sul Cancro (GENOVA)

Research output: Contribution to journal › Letter › peer-review

Abstract

Patients with multiple sclerosis (MS) who present coronavirus disease 2019 (COVID-19) are of particular interest to neurologists. These patients have a neuroimmune disease and receive immunomodulatory or immunosuppressive therapies in the long-term. We present here data from 73 patients with MS and a confirmed diagnosis of COVID-19 from five Latin American countries. Fifteen patients (20.5%) were hospitalized and two patients died. The use of anti-CD20 therapies was the only risk factor associated to hospitalization and death. Despite the small sample size, this study highlights the awareness regarding therapeutic options for MS during the pandemic.

Original language	English
Article number	103173
Journal	Multiple Sclerosis and Related Disorders
Volume	55
DOIs	https://doi.org/10.1016/j.msard.2021.103173
Publication status	Published - Oct 2021

Keywords

COVID-19
Multiple sclerosis
ocrelizumab
Pandemic
rituximab

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1016/j.msard.2021.103173

Cite this

Fragoso, Y. D., Schiavetti, I., Carmisciano, L., Ponzano, M., Steinberg, J., Treviño-Frenk, I., Ciampi, E., Vecino, M. C. A., Correa, E. P., Carcamo, C., Gomes, S., Pimentel, M. L. V., Santos, G. A. C., Vrech, C., Winckler, T. C. A., & Sormani, M. P. (2021). Coronavirus disease 2019 in Latin American patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 55, [103173]. https://doi.org/10.1016/j.msard.2021.103173

Fragoso, YD, Schiavetti, I, Carmisciano, L, Ponzano, M, Steinberg, J, Treviño-Frenk, I, Ciampi, E, Vecino, MCA, Correa, EP, Carcamo, C, Gomes, S, Pimentel, MLV, Santos, GAC, Vrech, C, Winckler, TCA & Sormani, MP 2021, 'Coronavirus disease 2019 in Latin American patients with multiple sclerosis', Multiple Sclerosis and Related Disorders, vol. 55, 103173. https://doi.org/10.1016/j.msard.2021.103173

@article{8b2758b6f1904947a64c7a5b7b3cb606,

title = "Coronavirus disease 2019 in Latin American patients with multiple sclerosis",

abstract = "Patients with multiple sclerosis (MS) who present coronavirus disease 2019 (COVID-19) are of particular interest to neurologists. These patients have a neuroimmune disease and receive immunomodulatory or immunosuppressive therapies in the long-term. We present here data from 73 patients with MS and a confirmed diagnosis of COVID-19 from five Latin American countries. Fifteen patients (20.5%) were hospitalized and two patients died. The use of anti-CD20 therapies was the only risk factor associated to hospitalization and death. Despite the small sample size, this study highlights the awareness regarding therapeutic options for MS during the pandemic.",

keywords = "COVID-19, Multiple sclerosis, ocrelizumab, Pandemic, rituximab",

author = "Fragoso, {Yara D.} and Irene Schiavetti and Luca Carmisciano and Marta Ponzano and Judith Steinberg and Irene Trevi{\~n}o-Frenk and Ethel Ciampi and Vecino, {Maria Cecilia A.} and Correa, {Edgar P.} and Claudia Carcamo and Sidney Gomes and Pimentel, {Maria Lucia V.} and Santos, {Gutemberg A.C.} and Carlos Vrech and Winckler, {Thereza C.A.} and Sormani, {Maria Pia}",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier B.V.",

year = "2021",

month = oct,

doi = "10.1016/j.msard.2021.103173",

language = "English",

volume = "55",

journal = "Multiple Sclerosis and Related Disorders",

issn = "2211-0348",

publisher = "Elsevier",

}

TY - JOUR

T1 - Coronavirus disease 2019 in Latin American patients with multiple sclerosis

AU - Fragoso, Yara D.

AU - Schiavetti, Irene

AU - Carmisciano, Luca

AU - Ponzano, Marta

AU - Steinberg, Judith

AU - Treviño-Frenk, Irene

AU - Ciampi, Ethel

AU - Vecino, Maria Cecilia A.

AU - Correa, Edgar P.

AU - Carcamo, Claudia

AU - Gomes, Sidney

AU - Pimentel, Maria Lucia V.

AU - Santos, Gutemberg A.C.

AU - Vrech, Carlos

AU - Winckler, Thereza C.A.

AU - Sormani, Maria Pia

PY - 2021/10

Y1 - 2021/10

N2 - Patients with multiple sclerosis (MS) who present coronavirus disease 2019 (COVID-19) are of particular interest to neurologists. These patients have a neuroimmune disease and receive immunomodulatory or immunosuppressive therapies in the long-term. We present here data from 73 patients with MS and a confirmed diagnosis of COVID-19 from five Latin American countries. Fifteen patients (20.5%) were hospitalized and two patients died. The use of anti-CD20 therapies was the only risk factor associated to hospitalization and death. Despite the small sample size, this study highlights the awareness regarding therapeutic options for MS during the pandemic.

AB - Patients with multiple sclerosis (MS) who present coronavirus disease 2019 (COVID-19) are of particular interest to neurologists. These patients have a neuroimmune disease and receive immunomodulatory or immunosuppressive therapies in the long-term. We present here data from 73 patients with MS and a confirmed diagnosis of COVID-19 from five Latin American countries. Fifteen patients (20.5%) were hospitalized and two patients died. The use of anti-CD20 therapies was the only risk factor associated to hospitalization and death. Despite the small sample size, this study highlights the awareness regarding therapeutic options for MS during the pandemic.

KW - COVID-19

KW - Multiple sclerosis

KW - ocrelizumab

KW - Pandemic

KW - rituximab

UR - http://www.scopus.com/inward/record.url?scp=85111283054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85111283054&partnerID=8YFLogxK

U2 - 10.1016/j.msard.2021.103173

DO - 10.1016/j.msard.2021.103173

M3 - Letter

AN - SCOPUS:85111283054

VL - 55

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

SN - 2211-0348

M1 - 103173

ER -

Coronavirus disease 2019 in Latin American patients with multiple sclerosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this